ArticleInternational journal of cardiology. Cardiovascular risk and prevention2025
Association between cardiac rehabilitation and LDL-levels, adherence to guideline-recommended medication and mortality rate after myocardial infarction.
Article in International journal of cardiology. Cardiovascular risk and prevention, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Depression, health anxiety, and five-year mortality after ST-elevation myocardial infarction: the SEMI-CI cohort.International journal of cardiology. Cardiovascular risk and prevention · 2026Article
- Comment on "Association between cardiac rehabilitation and LDL-levels, adherence to guideline-recommended medication and mortality rate after myocardial infarction".International journal of cardiology. Cardiovascular risk and prevention · 2026Article
- Circulating-free DNA: A promising tool for early detection of myocardial infarction.International journal of cardiology. Cardiovascular risk and prevention · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: This study aims to identify three-month and one year mortality rate, LDL level and adherence to guideline-recommended medication in patients with myocardial infarct (MI) receiving cardiac rehabilitation (CR) compared to patients who do not. Method: In this retrospective study, patients hospitalized in North Denmark Regional Hospital in Hjoerring (capture population 200.000) with acute coronary syndrome between January 1st, 2017, to December 31st, 2021, were included. Baseline characteristics, initial treatment of revascularization and all-cause mortality were examined through the Danish National Patient Registry, the Regional Cardiac Rehabilitation Database, and medical chart review. Patients were grouped by revascularization (yes/no) during hospitalization and CR. Adjusted Cox proportional regression model was used to assess differences in mortality and LDL levels. Results: A total of 1209 myocardial infarction (MI) survivors were included in this study. A total of 1209 myocardial infarction (MI) survivors were included. Significant LDL reductions at 6- and 12-month follow-ups were observed in patients receiving both cardiac rehabilitation (CR) and lipid-modifying therapy at baseline (p = .001), but not in those without CR. In revascularized patients, use of multiple antithrombotic agents was lower in the no CR group at three months (57.1 % vs 78.8 %, p = .002) and one year (60 % vs 78.5 %, p = .010). Three-month mortality rate was higher among patients who did not undergo CR, both in the revascularization group (19 % vs 2 %, p = 0.001) and the non-revascularization group (18 % vs 3 %, p = 0.001). Conclusion: Patients undergoing CR were associated with lower LDL-levels, higher adherence to guideline-recommended medication and lower mortality rate at three-month follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.